Alejandro Majlis

3.1k total citations · 1 hit paper
20 papers, 2.4k citations indexed

About

Alejandro Majlis is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alejandro Majlis has authored 20 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alejandro Majlis's work include Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Alejandro Majlis is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Alejandro Majlis collaborates with scholars based in Chile, United States and Brazil. Alejandro Majlis's co-authors include Jaffer A. Ajani, Eric Van Cutsem, Vladimir Moiseyenko, M Fodor, Yee Chao, Sergei Tjulandin, Manuel Constenla, C. Boni, Adriano Rodrigues and Э К Возный and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Alejandro Majlis

19 papers receiving 2.4k citations

Hit Papers

Phase III Study of Docetaxel and Cisplatin Plus Fluoroura... 2006 2026 2012 2019 2006 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
    2006 1.5k citations Eric Van Cutsem, Vladimir Moiseyenko et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alejandro Majlis Chile 14 1.9k 1.3k 892 637 287 20 2.4k
A. Lecesne France 15 1.3k 0.7× 563 0.4× 571 0.6× 1.1k 1.7× 162 0.6× 39 2.1k
César Serrano Spain 24 1.3k 0.7× 459 0.4× 585 0.7× 1.1k 1.8× 196 0.7× 103 2.1k
Э К Возный Portugal 5 1.6k 0.9× 1.3k 1.0× 784 0.9× 568 0.9× 94 0.3× 6 2.5k
Wasat Mansoor United Kingdom 23 1.9k 1.0× 1.9k 1.5× 1.0k 1.2× 655 1.0× 223 0.8× 98 3.1k
Hirokazu Taniguchi Japan 32 2.2k 1.2× 1.0k 0.8× 1.5k 1.7× 1.1k 1.7× 426 1.5× 113 3.3k
Francis Daniel United Kingdom 5 1.5k 0.8× 960 0.7× 775 0.9× 532 0.8× 131 0.5× 5 2.0k
Gina Z. D’Amato United States 16 1.0k 0.5× 447 0.3× 280 0.3× 538 0.8× 176 0.6× 75 1.3k
Manuel Constenla Spain 19 2.2k 1.2× 2.0k 1.5× 909 1.0× 591 0.9× 147 0.5× 53 3.1k
Javier Martínez‐Trufero Spain 20 1.1k 0.6× 976 0.8× 533 0.6× 175 0.3× 207 0.7× 124 2.0k
Rodrigo Ruiz‐Soto United States 16 544 0.3× 438 0.3× 242 0.3× 526 0.8× 215 0.7× 61 1.3k

Countries citing papers authored by Alejandro Majlis

Since Specialization
Citations

This map shows the geographic impact of Alejandro Majlis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandro Majlis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandro Majlis more than expected).

Fields of papers citing papers by Alejandro Majlis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alejandro Majlis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandro Majlis. The network helps show where Alejandro Majlis may publish in the future.

Co-authorship network of co-authors of Alejandro Majlis

This figure shows the co-authorship network connecting the top 25 collaborators of Alejandro Majlis. A scholar is included among the top collaborators of Alejandro Majlis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alejandro Majlis. Alejandro Majlis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zinzani, Pier Luigi, Catherine Thiéblemont, В Я Мельниченко, et al.. (2023). Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170. Blood. 142(2). 141–145. 31 indexed citations
2.
Pinto, Mauricio P., Laura Cereceda, Jose Reyes, et al.. (2022). Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience. Journal of Personalized Medicine. 12(2). 195–195. 2 indexed citations
3.
Zinzani, Pier Luigi, Catherine Thiéblemont, В Я Мельниченко, et al.. (2021). Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). Blood. 138(Supplement 1). 306–306. 5 indexed citations
4.
Zinzani, Pier Luigi, В Я Мельниченко, Krimo Bouabdallah, et al.. (2020). Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study. Blood. 136(Supplement 1). 42–43. 1 indexed citations
5.
Zinzani, Pier Luigi, Catherine Thiéblemont, В Я Мельниченко, et al.. (2017). Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial. Hematological Oncology. 35(S2). 62–63. 16 indexed citations
6.
Roa, Iván, et al.. (2013). Mutación del gen KRAS en el cáncer de colon y recto. Revista médica de Chile. 141(9). 1166–1172. 17 indexed citations
7.
Saliba, Rima M., Alejandro Majlis, Gabriela Rondón, et al.. (2011). Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization,. Blood. 118(21). 4058–4058.
8.
Paredes, Laura Gallego, et al.. (2010). Mobilization and Collection of Peripheral Blood Stem Cells: Guidelines for Blood Volume to Process, Based on CD34-Positive Blood Cell Count in Adults and Children. Transplantation Proceedings. 42(1). 339–344. 17 indexed citations
9.
Ajani, Jaffer A., Vladimir Moiseyenko, Sergei Tjulandin, et al.. (2007). Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group. Journal of Clinical Oncology. 25(22). 3205–3209. 208 indexed citations
10.
Ajani, Jaffer A., Vladimir Moiseyenko, Sergei Tjulandin, et al.. (2007). Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group. Journal of Clinical Oncology. 25(22). 3210–3216. 158 indexed citations
11.
Cutsem, Eric Van, Vladimir Moiseyenko, Sergei Tjulandin, et al.. (2006). Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. Journal of Clinical Oncology. 24(31). 4991–4997. 1480 indexed citations breakdown →
12.
Ajani, Jaffer A., M Fodor, Sergei Tjulandin, et al.. (2005). Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma. Journal of Clinical Oncology. 23(24). 5660–5667. 179 indexed citations
13.
Heredia, Fernando Martínez, et al.. (2005). Neoadjuvant combined chemotherapy followed by external whole pelvic irradiation in two cases of primary extranodal non-Hodgkin's lymphoma of the uterine cervix. Gynecologic Oncology. 97(1). 285–287. 22 indexed citations
14.
Moiseyenko, Vladimir, Jaffer A. Ajani, S. Tjulandin, et al.. (2005). Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Journal of Clinical Oncology. 23(16_suppl). 4002–4002. 59 indexed citations
15.
Vallejos, Carlos, Hernán Carranza, M Fodor, et al.. (1999). Taxotere® (T) and doxorubicin (D) combination: a phase II South American study in first line treatment (tt) of metastatic breast cancer (MBC). European Journal of Cancer. 35. S329–S329. 3 indexed citations
16.
Cortes, Jörge E., Moshe Talpaz, S O'Brien, et al.. (1998). Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.. Journal of Clinical Oncology. 16(10). 3279–3285. 26 indexed citations
17.
Majlis, Alejandro, William Pugh, Maria Alma Rodriguez, William F. Benedict, & Fernando Cabanillas. (1997). Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants.. Journal of Clinical Oncology. 15(4). 1664–1671. 100 indexed citations
18.
Majlis, Alejandro, Terry L. Smith, Moshe Talpaz, et al.. (1996). Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.. Journal of Clinical Oncology. 14(1). 196–203. 63 indexed citations
19.
Cabanillas, Fernando, et al.. (1995). Outcome of Hodgkin's disease in elderly patients. Hematological Oncology. 13(1). 19–27. 26 indexed citations
20.
Majlis, Alejandro, et al.. (1992). [Immunologic study of lymphoproliferative diseases].. PubMed. 120(7). 772–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Lecesne Breakdown of academic impact, for papers by César Serrano Breakdown of academic impact, for papers by Э К Возный Breakdown of academic impact, for papers by Wasat Mansoor Breakdown of academic impact, for papers by Hirokazu Taniguchi Breakdown of academic impact, for papers by Francis Daniel Breakdown of academic impact, for papers by Gina Z. D’Amato Breakdown of academic impact, for papers by Manuel Constenla Breakdown of academic impact, for papers by Javier Martínez‐Trufero Breakdown of academic impact, for papers by Rodrigo Ruiz‐Soto
Rankless by CCL
2026